SCHEMBL5881166

SCHEMBL5881166

CC(=O)NC1(C(=O)O)Cc2c([nH]c3ccccc23)C(C2CC(C)CCC2C(C)C)C1

nearest known ligand 0.37

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
RB1 P06400 3/20 0.36
CHRNA7 P36544 1/20 0.35
TACR1 P25103 1/20 0.35
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TRPM8 Q7Z2W7 1/20 0.35
LMNA P02545 1/20 0.33
KCNA5 P22460 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5880946 0.90 TACR1 (0.45) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL5881089 0.78 KDM4E (0.41) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL5881165 0.72 TACR1 (0.52) KDM4EALDH1A1HPGDRB1TACR1
SCHEMBL5880965 0.68 TACR1 (0.60) MAPTTACR1LMNA
SCHEMBL5881088 0.60 TACR1 (0.66) KDM4EALDH1A1MAPTHPGDTACR1
SCHEMBL8023187 0.57 TRPM8 (0.43) MEN1KMT2AALDH1A1HTTTRPM8
SCHEMBL4880157 0.56 HTR2C (0.52) KDM4EALDH1A1MAPTLMNAKCNA5
SCHEMBL6609382 0.56 TACR1 (0.51) KMT2AKDM4EALDH1A1MAPTHPGD
SCHEMBL4083810 0.56 TRPM8 (0.85) TRPM8KCNA5
SCHEMBL4081078 0.56 TRPM8 (0.85) TRPM8KCNA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030232873-A1 Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) ZENTARIS AG (DE) 2003-12-18 US claimed
US-7122570-B2 Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) ZENTARIS AG (DE) 2006-10-17 US disclosed
EP-1453803-A2 TETRAHYDROCARBOZOLE DERIVATIVES AS LIGANDS FOR G-PROTEIN COUPLED RECEPTORS (GPCR) Zentaris GmbH (DE) 2004-09-08 EP disclosed
US-20030232873-A1 Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) ZENTARIS AG (DE) 2003-12-18 US disclosed
WO-2003051837-A2 TETRAHYDROCARBOZOLE DERIVATIVES AS LIGANDS FOR G-PROTEIN COUPLED RECEPTORS (GPCR) ZENTARIS GMBH (DE) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232873-A1 Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) GPR4, GPR88, GPR35 MEN1 2877/4885KMT2A 3412/4885KDM4E 1611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.